-
Subject Areas on Research
-
A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation.
-
A randomized, prospective double-blind comparison of the efficacy of generic propofol (sulphite additive) with diprivan.
-
ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee.
-
Aerosolized ribavirin: the most expensive drug for pneumonia.
-
Assessing bioequivalence and drug interchangeability.
-
Authors' Reply to Courtney Suggs and Colleagues' Comment on: "Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs".
-
Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial.
-
Bioequivalence review for drug interchangeability.
-
Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
-
Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications.
-
Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.
-
Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.
-
Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
-
Does generic entry always increase consumer welfare?
-
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review.
-
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
-
Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms.
-
Frequency estimator for assessing of follow-on biologics.
-
Generic and branded drugs for the treatment of people living with HIV/AIDS.
-
Generic clopidogrel: time to substitute?
-
Global health and university patents.
-
Haloperidol for postoperative nausea and vomiting: are we reinventing the wheel?
-
Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis.
-
Improving Medication Adherence in Cardiometabolic Disease: Practical and Regulatory Implications.
-
Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
-
Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs.
-
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
-
On assessing bioequivalence and interchangeability between generics based on indirect comparisons.
-
On safety margin for drug interchangeability.
-
Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry.
-
Provider and patient drivers of ototopical antibiotic prescription variability.
-
Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations.
-
Rocephin--the thin end of the wedge.
-
Should Physicians be Encouraged to use Generic Names and to Prescribe Generic Drugs?
-
Some thoughts on drug interchangeability.
-
Statistical and regulatory considerations in assessments of interchangeability of biological drug products.
-
Statistical evaluation of the scaled criterion for drug interchangeability.
-
Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults.
-
The bootstrap procedure in individual bioequivalence.
-
The impact of evidence-based education on prescribing in a psychiatry residency.
-
The impact of manufacturer coupon use in the statin market.
-
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
-
The state and consequences of dermatology drug prices in the United States.
-
Understanding therapeutic equivalence in epilepsy.
-
Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine.